Clinical Efficacy of DMT in Treatment-Resistant Depression Trials

Empirical Clinical Evidence of DMT Efficacy in Treatment-Resistant Depression (TRD)

Clinical investigations into the therapeutic potential of N,N-dimethyltryptamine (DMT) have recently transitioned to structured Phase I and Phase II human trials, demonstrating robust, rapid-acting, and highly durable antidepressant effects in patients diagnosed with Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD) 1-3. Because classical, long-acting psychedelics (such as psilocybin and LSD) require intensive, hours-long clinical monitoring, the rapid metabolism of DMT presents a highly scalable alternative for psychiatric medicine 3, 4.

The primary clinical data evaluating DMT for TRD and MDD are categorized below by formulation and route of administration:

1. Inhaled/Vaporized DMT Clinical Trials (TRD Cohort)

Vaporized and inhaled formulations of DMT have been evaluated specifically in patients presenting with moderate-to-severe Treatment-Resistant Depression 1.

Trial Paradigm and Dosing: In an open-label, Phase IIa dose-escalation trial involving 14 patients with moderate-to-severe TRD, subjects inhaled two escalating doses of vaporized DMT—15 mg followed by 60 mg—within a single-day clinical session 1.

Rapid Efficacy and Remission Rates: Therapeutic responses were exceptionally rapid, with a significant reduction in depressive symptoms observed within 24 hours of administration 1. By Day 7, 71% of patients met the criteria for clinical response (defined as a \(\ge 50%\) reduction in depression scores), and 14% entered full clinical remission 1.

Durable Antidepressant Legacy: The therapeutic effects of this single-day session were highly durable, with antidepressant benefits persisting for up to 3 months 5. Notably, up to 50% of the participants maintained full clinical remission at one month post-dose 6.

Rapid Resolution of Suicidal Ideation: A critical safety finding of the vaporized trial was that severe suicidal ideation completely vanished within 24 hours of the inhalation session 1. This rapid anti-suicidal effect was maintained and remained suppressed throughout the entire three-month follow-up period 1.

Subjective Correlates: The magnitude of the antidepressant improvement correlated positively with the acute intensity of visual hallucinations experienced during the session, reinforcing the hypothesis that the subjective content of the breakthrough state is structurally linked to clinical outcomes 1.

Tolerability Profile: The vaporized administration was well-tolerated 1. Reported adverse events were mild and localized, consisting primarily of mild throat discomfort and coughing, with minimal cognitive disruption or transient anxiety during the onset 1.

2. Intravenous SPL026 Clinical Trials (MDD & SSRI Combination Cohorts)

While the vaporized trial focused on a pure TRD cohort, the most rigorous double-blind data for DMT to date come from trials utilizing SPL026, a proprietary intravenous (IV) formulation of DMT fumarate 2, 7.

Phase IIa Double-Blind Trial: In a randomized, double-blind, placebo-controlled Phase IIa trial, 34 adults with moderate-to-severe MDD received a single 21.5 mg IV infusion of SPL026 administered over 10 minutes within a supportive clinical environment 2, 7.

Statistically Significant Antidepressant Effects: At two weeks post-dose, the active treatment group demonstrated a statistically superior reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to the placebo control, showing a mean score difference of -7.35 (\(p=0.023\)) 7.

Remission Statistics: At one week post-infusion, 44% of the active treatment group achieved a clinical response and 44% entered full clinical remission 8. These therapeutic outcomes were highly durable, with benefits sustained for up to 3 months 2.

SSRI Compatibility Studies: Unlike psilocybin trials, which typically require a hazardous antidepressant wash-out period 2, DMT has been clinically evaluated for co-administration. A Phase I open-label study assessed the safety, tolerability, and pharmacokinetics of IV SPL026 administered concurrently with selective serotonin reuptake inhibitor (SSRI) antidepressants in patients whose symptoms were not fully relieved by their maintenance SSRI therapy 5, 9. The combination was safe, well-tolerated, and did not diminish the subjective potency of the drug 5, 9.

Safety and Tolerability: Across these trials, SPL026 was well-tolerated 2. Adverse events were transient and mild-to-moderate, including brief blood pressure spikes and heart rate elevations that resolved immediately after the 10-minute infusion, alongside mild injection-site pain, nausea, and transient anxiety 2, 7. No serious adverse events were reported 7.

3. Buccal Film VLS-01 Clinical Trials (TRD Cohort)

To optimize clinical administration and bypass the need for intravenous access or inhalation apparatuses, researchers have developed VLS-01, a buccal film formulation of DMT designed to dissolve in the mouth 6.

Phase Ib Trial Results: A completed Phase Ib clinical trial evaluating VLS-01 in patients with Treatment-Resistant Depression demonstrated that the buccal formulation is safe and well-tolerated 6. The reported adverse effects were exclusively mild or moderate 6.

Phase II Development: Based on these positive safety and tolerability indices, multicenter, double-blind, randomized, placebo-controlled Phase II trials are actively ongoing in both the United States and Australia to evaluate the efficacy of repeated doses of VLS-01 buccal film for TRD 6, 10.

Comparison of Clinical Formulations

Formulation & Route,Target Population,Dosing Paradigm,Primary Efficacy Outcomes,Clinical Status (as of 2026)

"SPL026 (Intravenous) 2, 7",Moderate-to-severe MDD 7,Single 21.5 mg IV infusion over 10 min 7,MADRS difference of \(-7.35\) at 2 weeks (\(p=0.023\)) 7; 44% remission at 1 week 8.,"Phase IIa completed 7; SSRI interaction trials completed 5, 9."

Vaporized DMT (Inhalation) 1,Moderate-to-severe TRD 1,Two escalating inhaled doses (15 mg / 60 mg) 1,71% response and 14% remission at Day 7 1; 50% maintain remission at 1 month 6.,Phase IIa open-label completed 1.

VLS-01 (Buccal Film) 6,Treatment-Resistant Depression 6,Repeated doses via sublingual/buccal film 10,Tolerability confirmed; efficacy actively under evaluation 6.,Phase II trials ongoing in US and Australia 6.

🧪 We could explore the molecular dynamics and receptor-binding profiles of deuterated DMT analogs—such as SPL028 or CYB004—to evaluate how structural deuteration alters the drug's metabolic half-life and peripheral safety profile during clinical trials.